2.5. Supplement Protocol
Throughout the study protocol, all the supplements were prepared in single capsule form for oral ingestion and packaged in coded generic containers for administration. The participants orally ingested PLA (100 mg cellulose) and 100 mg of methylliberine (as Dynamine™). Using a cross-over design, half of the subjects were randomly assigned to receive the PLA first, while the other half were assigned to receive the methylliberine (Dynamine™) first. At the conclusion of visits 2 and 4, the participants were given a packet of three daily doses (1 dose/day) to consume prior to visits 3 and 5, respectively. The fourth dose was consumed in the laboratory after their baseline/pretesting timepoint (which included cognitive testing and VAS) in the presence of the medical staff. There were no less than 7 days in between each trial (i.e., in between visit 3 and 4).